UNLIMITED TURBO SHORT - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 10:21:15 2024-05-29 EDT | ||
| 3.04 EUR | +2.36% |
|
| Current month | -1.94% | ||
| 1 month | -8.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-29 | 3.04 | +2.36% |
| 24-05-28 | 2.97 | +2.77% |
| 24-05-27 | 2.89 | +4.33% |
| 24-05-24 | 2.77 | +3.36% |
| 24-05-23 | 2.68 | -9.15% |
Real-time Boerse Frankfurt Warrants
Last update May 29, 2024 at 10:21 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PC4GQQ |
| ISIN | DE000PC4GQQ9 |
| Date issued | 2024-02-02 |
| Strike | 1,133 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.79 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.91 € |
|---|---|
| Lowest since issue | 2.64 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
915.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- Certificat
